

Medtronic TAVI ▾

Products ▾

Clinical guidelines

Clinical Evidence ▾

Treating Severe
Aortic Stenosis

MORE OPTIONS FOR MORE PATIENTS EVOLUT™ TAVI

THE FIRST AND ONLY TAVI PLATFORM CE MARKED

for treatment of patients
with severe BICUSPID aortic stenosis*

CE ženklinimas išplēstoms indikācijoms – dvīburē (bicuspid, - angl.) anatomijā

30-DAY OUTCOMES IN BICUSPID VS TRICUSPID¹ WITH EVOLUT™ PLATFORM

Strong clinical and procedure
outcomes at 30 days for patients
with bicuspid and tricuspid aortic
valves.¹



EVOLUT™ TAVI LOW RISK INDICATION

LEARN MORE

